In advanced/metastatic disease, systemic first-line therapeutic options are specific BRAF-inhibitors for BRAFV600E-mutated melanomas [82] as well as immune checkpoint inhibitors [83] but the understanding of emergence of acquired resistance to these therapies is still an unmet clinical need. The gene discussed is BRAF; the disease is melanoma.